hailshadow-istockphoto-com

Hailshadow / iStockphoto.com

17 September 2018Big Pharma

MSF critical of EPO decision to uphold Gilead’s hepatitis C patent

The European Patent Office (EPO) has upheld a patent covering Gilead’s hepatitis C medicine sofosbuvir, despite opposition from humanitarian organisation Médecins Sans Frontières (MSF).

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Appeal filed against EPO sofosbuvir patent decision

10 December 2018 Six organisations have appealed against the European Patent Office’s decision to uphold a patent for a key hepatitis C drug.

Gilead to launch generic versions of its hep C drugs

26 September 2018 Gilead is set to produce cheaper authorised generic versions of its branded hepatitis C treatments from 2019.

MSF challenges Gilead patent application in China

21 December 2017 Médecins Sans Frontières has challenged a patent application filed by Gilead in China, claiming that the rejection of the patent would “pave the way towards the availability of affordable generic versions”.

More on this story

Appeal filed against EPO sofosbuvir patent decision

10 December 2018 Six organisations have appealed against the European Patent Office’s decision to uphold a patent for a key hepatitis C drug.

Gilead to launch generic versions of its hep C drugs

26 September 2018 Gilead is set to produce cheaper authorised generic versions of its branded hepatitis C treatments from 2019.

MSF challenges Gilead patent application in China

21 December 2017 Médecins Sans Frontières has challenged a patent application filed by Gilead in China, claiming that the rejection of the patent would “pave the way towards the availability of affordable generic versions”.

More on this story

Appeal filed against EPO sofosbuvir patent decision

10 December 2018 Six organisations have appealed against the European Patent Office’s decision to uphold a patent for a key hepatitis C drug.

Gilead to launch generic versions of its hep C drugs

26 September 2018 Gilead is set to produce cheaper authorised generic versions of its branded hepatitis C treatments from 2019.

MSF challenges Gilead patent application in China

21 December 2017 Médecins Sans Frontières has challenged a patent application filed by Gilead in China, claiming that the rejection of the patent would “pave the way towards the availability of affordable generic versions”.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’

BMS unit loses cell therapy patent at European Patent Office

Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market

Lord Justice Birss to become chancellor of the High Court

Bankruptcy judge approves $305m sale of genetics testing company

Sanofi successfully challenges rare disease patent in Europe

Bayer appoints new head of IP

WATCH: Policy direction—where are we now?